Edition:
United States

Shanghai Fosun Pharmaceutical Group Co Ltd (600196.SS)

600196.SS on Shanghai Stock Exchange

30.75CNY
21 Apr 2017
Change (% chg)

¥-0.25 (-0.81%)
Prev Close
¥31.00
Open
¥31.01
Day's High
¥31.35
Day's Low
¥29.99
Volume
13,723,755
Avg. Vol
9,581,375
52-wk High
¥31.50
52-wk Low
¥18.25

Latest Key Developments (Source: Significant Developments)

Curasan enters into exclusive distribution partnership with China-based Fosun Group
Wednesday, 19 Apr 2017 03:06am EDT 

April 19 (Reuters) - Curasan AG :Enters into exclusive distribution partnership with China-based Fosun Group.Portfolio expansion and new permits planned for China.Anticipates a clear sales and revenue contribution for current 2017 fiscal year resulting from new distribution agreement, which will be offset by expected market entry costs.Expects to see positive earnings from partnership starting in 2018.  Full Article

Shanghai Fosun Pharmaceutical says unit and Chindex (BVI) entered into SPA
Friday, 7 Apr 2017 10:01am EDT 

Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>: Unit entered into share purchase agreement in relation to purchase of sale shares . Ample Up, a wholly-owned subsidiary of the company, and Chindex (BVI) entered into the share purchase agreement . Deal for consideration of RMB263.6 mln .Ample Up agreed to purchase and Chindex (BVI) agreed to sell sale shares.  Full Article

Shanghai Fosun Pharmaceutical responds to media reports
Thursday, 30 Mar 2017 12:26am EDT 

Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>: Reference is made to announcements of Shanghai Fosun Pharmaceutical (Group) Co., dated 28 July 2016 . Recently, there have been media reports provide that acquisition was approved by relevant competent authorities of India . Acquisition was approved by shareholders at 2016 third extraordinary general meeting of company . Relevant approvals of competent authorities of PRC in relation to acquisition have been obtained . Acquisition was reviewed by Indian foreign investment promotion board . Filings with competent antitrust authorities of united states have been completed .Acquisition will be recommended to cabinet committee on economic affairs of India for further review and approval.  Full Article

Shanghai Fosun Pharmaceutical Group to pay cash 3.5 yuan per 10 shares as FY 2016 div payment
Wednesday, 29 Mar 2017 04:05am EDT 

Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS> :Says it plans to pay cash 3.5 yuan per 10 shares as FY 2016 div payment.  Full Article

Shanghai Fosun Pharmaceutical to issue up to 10 bln yuan debt financing tools
Tuesday, 28 Mar 2017 09:27am EDT 

Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS><2196.HK> : Says 2016 net profit up 14.1 percent y/y .Says it plans to issue up to 10 billion yuan ($1.45 billion) debt financing instruments.  Full Article

Shanghai Fosun Pharmaceutical Group issues first tranche corporate bonds worth 1.25 bln yuan
Wednesday, 15 Mar 2017 03:59am EDT 

Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS> :Says it issued first tranche corporate bonds worth 1.25 billion yuan, with coupon rate 4.5 percent.  Full Article

Shanghai Fosun Pharma says reports on its bid for Germany's Stada inaccurate
Friday, 10 Mar 2017 05:37am EST 

Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS><2196.HK> :Says media reports on its bid for Germany's Stada worth 3.6 billion euros ($3.82 billion) are inaccurate.  Full Article

Shanghai Fosun Pharmaceutical says no plans or arrangements in relation to bidding
Friday, 10 Mar 2017 05:30am EST 

Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS> : Recently, there have been media reports on co's plan to join bidding for acquisition of Stada Arzneimittel AG .Company has no plans or arrangements in relation to bidding mentioned in media reports.  Full Article

Kite Pharma names Richard Wang CEO of Fosun Kite Biotechnology Co Ltd
Sunday, 5 Mar 2017 04:00pm EST 

Kite Pharma Inc : Richard L. Wang named chief executive officer of Fosun Kite Biotechnology Co, Ltd, a joint venture to lead development of axicabtagene ciloleucel and other engineered T-cell therapies for treatment of cancers in China .Richard wang named CEO of Fosun Kite Biotechnology Co Ltd.  Full Article

Shanghai Fosun Pharma's president increased H-shares holdings in the company
Thursday, 19 Jan 2017 05:00am EST 

Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS><2196.HK> :Says President Wu Yifang has bought 16,000 H-share in the company on Jan 19 at average price of about HK$24.92 per share.  Full Article

More From Around the Web